• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Overseas clinical trial data for IVD registration in China – Technical guidelines issued

Overseas clinical trial data for IVD registration in China – Technical guidelines issued

Clinical Trials GMP management
Tuesday, 25 January 2022 / Published in Medical Device, News, NMPA Registration in China

Overseas clinical trial data for IVD registration in China – Technical guidelines issued

Overseas clinical trial data for IVD registration in China now adopts the new technical guidelines issued (No.95-2021) on December 1, 2021, by the National Medical Products Administration (NMPA).

Based on the specific characteristics of the product, the applicant is required to submit a report that includes a comprehensive analysis of the differences between domestic and foreign clinical trials and its cause and effect to the domestic and foreign clinical trial data, in order to determine whether existing overseas clinical trial data is sufficient for registration approval in China.

The guideline lists out the common differences between domestic and foreign clinical trials:

  • Differences in the clinical trial design key elements
  • Differences in the comparison methods
  • Differences in the sample size
  • Differences in the subject population
  • Differences in the genetic information of different ethnic groups
  • Differences in the characteristics of diseases
  • Differences with the technical guidelines

Different statistical analysis used in domestic and foreign clinical trials could also be a factor leading to differences in the clinical trial data. When using overseas clinical trial data as clinical evidence for the application of NMPA registration, the applicant should evaluate it‘s eligibility and scientificity to explain why supplementary clinical trials will not be required in China.

For more information on the clinical trial data submission requirements for medical device and IVD registrations in China, feel free to read our blog post on the technical review guidelines issued in November 2021, or contact Cisema to learn more.

By Alice Liu and Jacky Li.

Tagged under: clinical trial data, Clinical Trials, In vitro diagnostics, IVDs

What you can read next

Draft Regulation for Drug-Device Combination Product Registration in China
supervision of medical device manufacturing
Supervision of Medical Device Manufacturing in China – 2022 Regulatory Updates
Latest Technical Review Guidelines Issued / Updated

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP